21.5 C
New York
Saturday, June 3, 2023

Searching For Real Value In Market Debris At FibroGen Inc. (NASDAQ: FGEN)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for FibroGen Inc. (FGEN) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $17.64. The FibroGen Inc. has recorded 11,214 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

FibroGen Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $17.64 and fluctuated between $17.98 as its day high and $17.35 as its day low. The current market capitalization of FibroGen Inc. is $1.72B. A total of 0.88 million shares were traded on the day, compared to an average of 908.12K shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, FGEN has seen 16 BUY and 23 SELL insider trades, representing the acquisition of 312,173 and the disposition of 152,884 shares. Over the last 12 months, there were 24 BUYs and 53 SELLs from insiders. Insiders purchased 438,389 shares during that period but sold 201,779.

In the most recent transaction, Conterno Enrique A sold 1,869 shares of FGEN for 19.52 per share on Apr 10. After the transaction, the Chief Executive Officer now owns 382,999 company shares. In a previous transaction on Apr 04, Eisner Mark sold 9,182 shares at 18.78 per share. FGEN shares that Chief Medical Officer owns now total 165,994.

Among the insiders who sold shares, Chung Christine disposed of 6,590 shares on Apr 04 at a per-share price of $18.78. This resulted in the SVP, China Operations holding 252,460 shares of FGEN after the transaction. In another insider transaction, Wettig Thane sold 905 shares at $18.71 per share on Mar 23. Company shares held by the Chief Commercial Officer now total 110,653.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for FGEN in the last 3 months, the mean price target is $26.46 with high estimates of $37.20 and low estimates of $16.00. In terms of 52-week highs and lows, FGEN has a high of $25.69 and a low of $8.15.

As of this writing, FGEN has an earnings estimate of -$0.71 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.62 per share and a lower estimate of -$0.78. The company reported an EPS of -$0.7 in the last quarter, which was 25.50% higher than expectations of -$0.94.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. FGEN’s latest balance sheet shows that the firm has $405.19M in Cash & Short Term Investments as of fiscal 2021. There were $99.73M in debt and $225.50M in liabilities at the time. Its Book Value Per Share was -$0.52, while its Total Shareholder’s Equity was $229.11M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FGEN is Buy with a score of 3.43.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles